Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...

Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could ...

Texas Attorney General Ken Paxton and Health Choice Alliance are accusing Eli Lilly of “incentivizing” providers in the state ...

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and ...

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...

Texas Attorney General Ken Paxton is accusing Eli Lilly and Co. of a kickback scheme to induce medical providers to prescribe ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern over the use of unapproved GLP-1 receptor agonists for weight loss, such as ...

We read with interest the Correspondence by Zhiqi Yao and colleagues1 published in The Lancet Diabetes & Endocrinology, which ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...